Senator Cassidy Releases Discussion Draft That Would Significantly Restrict Covered Entities’ Use of the 340B Program

7/10/2026 – Senator Cassidy Releases Discussion Draft That Would Significantly Restrict Covered Entities’ Use of the 340B Program Overview On June 25, 2026, Senator Bill Cassidy (R-La.), Chairman of the…

Eighth Circuit Rejects Novartis’ Request to Enjoin Missouri’s Contract Pharmacy Law

7/10/2026 – Eighth Circuit Rejects Novartis’ Request to Enjoin Missouri’s Contract Pharmacy Law On July 1, 2026, the United States Court of Appeals for the Eighth Circuit ruled that Novartis…

CMS Proposes Significant Cut in Medicare Reimbursement to Hospitals for 340B Drugs

7/9/2026 – CMS Proposes Significant Cut in Medicare Reimbursement to Hospitals for 340B Drugs ASP minus 33.4 percent. CMS has proposed to reduce Medicare payments to hospitals for separately payable 340B drugs…

Proposal to Change Federal Funding Rules Threatens RWCs’ 340B Participation

07/07/2026 – Proposal to Change Federal Funding Rules Threatens RWCs’ 340B Participation Overview The federal government recently published a proposed rule that would substantially alter management of federal grant programs.…

Despite Substantial Stakeholder Concern, HRSA Sticks to Low Estimated Burden for a Rebate Model

6/24/2026 – Despite Substantial Stakeholder Concern, HRSA Sticks to Low Estimated Burden for a Rebate Model Overview HRSA continues to move forward with implementing a rebate model pilot, as evidenced…

HRSA Sends 340B Rebate Model Prerule to White House for Review

6/3/2026 – HRSA Sends 340B Rebate Model Prerule to White House for Review Overview Last week, HRSA sent a prerule document titled “Notice Regarding 340B Rebate Model Pilot Program” to the White…

Legal Fight Over HRSA’s Hospital Child Site Policy Continues, as Agency Appeals Court Decision

5/13/2026 – Legal Fight Over HRSA’s Hospital Child Site Policy Continues, as Agency Appeals Court Decision Overview HRSA has appealed a federal district court’s decision that vacated the agency’s eligibility and registration requirements for…

Gilead and Amphastar Start Using Truzo to Implement Contract Pharmacy Restrictions

5/11/2026 – Gilead and Amphastar Start Using Truzo to Implement Contract Pharmacy Restrictions Gilead and Amphastar recently became the fourth and fifth manufacturers to announce use of the Truzo platform operated by Kalderos…

AstraZeneca and BMS Jump on 340B Claims Data Submission Bandwagon For Entity-Owned Pharmacies

4/21/2026 – AstraZeneca and BMS Jump on 340B Claims Data Submission Bandwagon For Entity-Owned Pharmacies AstraZeneca and Bristol Myers Squibb (BMS) became the most recent manufacturers to require covered entities to submit data…

Drug Manufacturer AbbVie Sues HRSA Over the 340B Patient Definition

4/17/2026 – Drug Manufacturer AbbVie Sues HRSA Over the 340B Patient Definition Last week, the drug manufacturer AbbVie filed a federal lawsuit challenging HRSA’s long-standing definition of a 340B patient.…